Navigation Links
IDM Pharma Appoints Gregory J. Tibbitts to Board of Directors
Date:4/4/2008

IRVINE, Calif., April 4, 2008 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) announced today the appointment of Gregory J. Tibbitts to its board of directors, effective April 3, 2008. Mr. Tibbitts is currently the chief financial officer for CryoCor, Inc. (Nasdaq: CRYO), a San Diego-based medical device company and in this role has overseen the transition from a private to public company, as well as from a clinical stage company to the current commercial operation.

"Greg's extensive financial experience will be an asset to IDM Pharma's board of directors," said Timothy P. Walbert, president and chief executive officer of IDM Pharma. "In senior positions at both privately-held and publicly-traded companies, Greg has proven himself to be an executive with strong integrity and outstanding leadership abilities."

During his more than 19 years in the financial and pharmaceutical industries, Mr.Tibbitts has held senior positions in a number of other companies including chief financial officer at Elitra Pharmaceuticals, a privately held drug discovery company. In addition, Mr. Tibbitts served as senior manager at Ernst & Young LLP and division controller at ITT Residential Capital.

Mr. Tibbitts received a bachelor's degree from the University of San Diego and a master's degree from San Diego State University, and is a Certified Public Accountant.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes forward-looking statements that reflect management's current views of future events including statements regarding the Company's business activities and Mr. Tibbitts' participation on the Company's Board of Directors. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, whether the Company will be able to provide assurance regarding the quality of the existing L-MTP-PE data and to respond to the remaining issues with regard to the MAA, including verification of data quality and CMC items, to the satisfaction of the CHMP, whether the final opinion of the CHMP will be consistent with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that additional data from the Phase 3 clinical trial of L-MTP-PE and other information in any amendment to the NDA for L-MTP-PE submitted by the Company may not provide adequate support for regulatory approval of L-MTP-PE in the United States within the timeframe expected by the Company, if at all, whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities, and whether the cash resources of the Company will be sufficient to fund operations as planned. These and other risks affecting the Company and its drug development programs, intellectual property rights, personnel and business are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.


'/>"/>
SOURCE IDM Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Hepatitis C Conference on Wednesday, April 9th
2. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
3. Anadys Pharmaceuticals to Present at the CanAccord Adams Hepatitis C Conference
4. Excipients Help Pharma Extend Product Life, Profits
5. PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
6. PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business
7. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
8. Laureate Pharma Reports Record Growth for 2007
9. DiObex Announces Presentation of Scientific Poster at Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
10. Dragon Pharma announces 2007 full year financial results
11. Transgenomic Opens Pharmacogenomics Laboratory in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... ... Drug Administration (FDA) has granted the company’s orphan drug designation request covering BHV-4157 ... drug designation granted by the FDA. , Spinocerebellar ataxia is a rare, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Media Cybernetics, global image ... Cybernetics corporate branding reflects a results-driven revitalization for a company with a renewed ... components include a crisp, refreshed logo and a new web presence. , “I ...
(Date:5/23/2016)... Oxitec CEO Hadyn Parry will testify ... before the United States House Committee on Science, Space and ... controlling the spread of the Aedes aegypti mosquito, ... (Logo: http://photos.prnewswire.com/prnh/20150630/227348 ) Oxitec has pioneered ... in Brazil , Panama ...
(Date:5/22/2016)... (PRWEB) , ... May 22, 2016 , ... Doctors in ... in combating the asbestos cancer, malignant mesothelioma. Surviving Mesothelioma has just posted an article ... in the University of Rome’s Department of Clinical Sciences and Translational Medicine evaluated more ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):